First Time Loading...

Intercept Pharmaceuticals Inc
NASDAQ:ICPT

Watchlist Manager
Intercept Pharmaceuticals Inc Logo
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Watchlist
Price: 19 USD Market Closed
Updated: Apr 29, 2024

Intercept Pharmaceuticals Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intercept Pharmaceuticals Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Operating Income
-$55.1m
CAGR 3-Years
41%
CAGR 5-Years
29%
CAGR 10-Years
-6%
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$9.3B
CAGR 3-Years
32%
CAGR 5-Years
2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Intercept Pharmaceuticals Inc's Operating Income?
Operating Income
-55.1m USD

Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Operating Income amounts to -55.1m USD.

What is Intercept Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-6%

Over the last year, the Operating Income growth was 30%. The average annual Operating Income growth rates for Intercept Pharmaceuticals Inc have been 41% over the past three years , 29% over the past five years , and -6% over the past ten years .